Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015
Jun 30, 2015, 09:00 ET
FREMONT, Calif., June 30, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that the Company will host its inaugural R&D Day on July 14, 2015, from 8:00 a.m.- 1:00 pm EDT in New York City.
The Ardelyx senior management team will present an overview of the Company's pipeline programs, including its lead compound, tenapanor, which has completed Phase 2b clinical trials for the treatment of patients with IBS-C and patients with hyperphosphatemia on dialysis. Ardelyx will also present additional details on RDX022, its recently announced compound for the treatment of hyperkalemia, as well as earlier-stage pipeline candidates.
The event will feature in-depth presentations by the Company's executive management team, who will also be joined by Geoffrey A. Block, M.D., CCCI, associate clinical professor in medicine at the University of Colorado Health Sciences Center. Dr. Block will provide perspective on new and emerging therapies in the nephrology field for hyperphosphatemia and hyperkalemia.
A live audio webcast of this presentation will be available through a link in the Investor Relations section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available for 30 days at the site after the presentation.
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, the Company has discovered and designed tenapanor, which it is evaluating for the treatment of IBS-C and hyperphosphatemia in chronic kidney disease patients on dialysis. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients, and has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, a program licensed to Sanofi. Ardelyx is also independently advancing several research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
Share this article